What you need to know about Russia’s new cancer vaccine
Russia's Federal Medical Biological Agency (FMBA) announced the successful completion of preclinical trials for a new cancer vaccine.
Veronika Skvortsova, head of the FMBA, confirmed the development during the Eastern Economic Forum (EEF), stating that the results demonstrated safety and effectiveness. “The vaccine is now ready for use; we are awaiting official approval,” she said.
What you need to know
The FMBA reported that the vaccine showed significant results in reducing tumour size and slowing disease progression. Effectiveness ranged from 60% to 80%, depending on the type of cancer, and increased survival rates were also observed
The agency plans to first apply the vaccine to colorectal cancer treatment. According to the Moffitt Cancer Centre, survival chances are particularly strong with early detection. Patients diagnosed with stage 1 colon cancer have a survival rate exceeding 92% over five years.
Skvortsova explained that the vaccine development has taken several years, with the last three focused on mandatory preclinical studies. “The research spanned several years, with the last three dedicated to mandatory preclinical studies,” she said.
While awaiting official approval, the FMBA is also pursuing vaccine research for glioblastoma and melanoma.
This story is written and edited by the Global South World team, you can contact us here.
